Media Partners | Contributors | Advertise | Contact | Log in | Sunday 22 July 2018

The NHS is testing a cannabis product


Share This Article:

You read the title correctly. Turns out the NHS is seeking to test a cannabis vaporiser product, and in fact the Medipen has been on sale for a year now. It has gained great reviews from those who use it to help ease their suffering from depression, anxiety, arthritis and/or fibromyalgia.

According to the Independent, the cannabidiol (CBD) vaporiser is now being tested by the NHS, and the implications of that could be huge.

Cannabis is currently classified as a Schedule 1 drug by the Government, meaning it’s thought to have no therapeutic value and therefore cannot be lawfully possessed or prescribed. But Medipen’s CEO believes his product – one of the most popular of its kind in the world – being tested by the NHS could aid in creating a “properly regulated cannabis market” in the UK.

Medipen's CBD vaporiser

“We’ve recently been working very closely with a team of NHS production and regulatory support pharmacists who’ve been able to meticulously analyse our proprietary formulation for both safety and cannabinoid concentration,” managing director Jordan Owen told the Independent.

“As the UK’s industry leading consumer cannabis biotechnology company, we’re excited to have set a new benchmark in providing a much-needed sense of legitimacy to the UK’s rapidly growing legal cannabis industry.

“As the first consumer cannabis product to be tested by the NHS, we are confident that this will go a long way towards creating a properly regulated cannabis market in the UK and are extremely excited to see what the future holds.”

Medipen's CBD vaporiser

Anna Ermakova, a science officer with the Beckley Foundation, said that this is a positive first step towards changing the perception of cannabis: “It is good to see some progress. If you can show that CBD has benefits you can start testing whole cannabis plants for medical benefits.”

CBD is not psychoactive, unlike THC, and is already found in Sativex, a prescription-only multiple sclerosis spray.

“THC and CBD help with different illnesses, so there’s a different market for CBD”, she said.

Ermakova went to show there’s a benefit to medicine that includes both compounds, though, saying: “We (the Beckley Foundation) were one of the first to show CBD can counteract the negative effects of THC, such as memory loss.”

The Foundation is also embarking on its own study into CBD. After a small first study showing positive results from CBD on helping to quit smoking it’s soon to launch a bigger study over a longer period of time and with more subjects.

It seems like medical cannabis could be gaining some ground in the UK.

read more

HAVE YOUR SAY BELOW tap to comment
© 2018 is a website of BigChoice Group Limited | 10-12 The Circle, Queen Elizabeth Street, London, SE1 2JE | registered in England No 6842641 VAT # 971692974